- Tytuł:
- Progressive forms of multiple sclerosis: disease-modifying therapy review
- Autorzy:
-
Sapko, Klaudia
Szczepańska-Szerej, Anna
Jamroz-Wiśniewska, Anna
Kulczyński, Marcin
Marciniec, Michał
Rejdak, Konrad - Powiązania:
- https://bibliotekanauki.pl/articles/1167060.pdf
- Data publikacji:
- 2018
- Wydawca:
- Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
- Tematy:
-
Disease-modifying drugs
Multiple sclerosis
New therapy
Primary-progressive MS
Secondary-progressive MS - Opis:
- Multiple sclerosis (MS) is a demyelinating, inflammatory, autoimmune disease of the central nervous system which affects most commonly young adults. It has wide spectrum of clinical and radiological presentations with relapses or steady progression. Recent years have brought new reports on the pathogenesis of MS. This systematized the current MS classification and created new parameters describing the course of the disease, such as activity and progression. Attention has been paid to the need for new drugs that focus on the treatment of progressive MS. Until now, the primary and secondary progressive MS have been somewhat forgotten, and most of modifying-disease drugs have been registered in the treatment of relapsing-remitting subtype. In recent years, not only new drug has been registered for the treatment of progressive MS (ocrelizumab) and another one is planned to be approved soon (siponimod), but also indications of old medicines (interferon-beta1b, cladribine, mitoxantrone, cyclophosphamide, azathioprine) have been extended. Despite intensive development, there is still a great need to seek new drugs that will stop the progression of disability in MS patients.
- Źródło:
-
World Scientific News; 2018, 105; 157-167
2392-2192 - Pojawia się w:
- World Scientific News
- Dostawca treści:
- Biblioteka Nauki
Artykuł